AIM: The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR). METHODS: The study was prospective, randomized and included 152 (103 men and 49 women) consecutive patients with AF or Af of 3-48 h duration. Ibutilide is a selective class III antiarrhythmic agent which when administered intravenously can terminate AF and Af. Amiodarone is also a class III antiarrhythmic agent that when given intravenously or orally has proved to be more effective than other agents in terminating AF and Af [B.N. Singh, F.V. Mody, B. Lopez, J.S. Sarma. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol 1999 Nov 4; 84: 161R-173R.]. Seventy-nine patients (56 with AF and 23 with Af) that consisted group A were treated with ibutilide. Seventy-three (52 with AF and 21 with Af) consisted group B and were treated with intravenous infusion of amiodarone. RESULTS: The conversion rate of group A (ibutilide) was significantly higher than the conversion rate of group B (amiodarone) (80% vs. 57%, p=0.0054). As regards the kind of arrhythmia separately, for AF there wasn't significant difference (77% vs. 69%, p=ns) whereas for Af ibutilide was superior to amiodarone (87% vs. 29%, p=0.003). The conversion rates of ibutilide didn't differ for AF and Af (77% vs. 87%, p=ns). CONCLUSIONS:Ibutilide is more effective than amiodarone in converting recent-onset Af to SR whereas both drugs are equally effective in converting recent-onset AF to SR.
RCT Entities:
AIM: The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR). METHODS: The study was prospective, randomized and included 152 (103 men and 49 women) consecutive patients with AF or Af of 3-48 h duration. Ibutilide is a selective class III antiarrhythmic agent which when administered intravenously can terminate AF and Af. Amiodarone is also a class III antiarrhythmic agent that when given intravenously or orally has proved to be more effective than other agents in terminating AF and Af [B.N. Singh, F.V. Mody, B. Lopez, J.S. Sarma. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol 1999 Nov 4; 84: 161R-173R.]. Seventy-nine patients (56 with AF and 23 with Af) that consisted group A were treated with ibutilide. Seventy-three (52 with AF and 21 with Af) consisted group B and were treated with intravenous infusion of amiodarone. RESULTS: The conversion rate of group A (ibutilide) was significantly higher than the conversion rate of group B (amiodarone) (80% vs. 57%, p=0.0054). As regards the kind of arrhythmia separately, for AF there wasn't significant difference (77% vs. 69%, p=ns) whereas for Afibutilide was superior to amiodarone (87% vs. 29%, p=0.003). The conversion rates of ibutilide didn't differ for AF and Af (77% vs. 87%, p=ns). CONCLUSIONS:Ibutilide is more effective than amiodarone in converting recent-onset Af to SR whereas both drugs are equally effective in converting recent-onset AF to SR.
Authors: Ian G Stiell; Marco L A Sivilotti; Monica Taljaard; David Birnie; Alain Vadeboncoeur; Corinne M Hohl; Andrew D McRae; Judy Morris; Eric Mercier; Laurent Macle; Robert J Brison; Venkatesh Thiruganasambandamoorthy; Brian H Rowe; Bjug Borgundvaag; Catherine M Clement; Jennifer Brinkhurst; Erica Brown; Marie-Joe Nemnom; George A Wells; Jeffrey J Perry Journal: CJEM Date: 2021-01-18 Impact factor: 2.410
Authors: Demosthenes G Katritsis; Giuseppe Boriani; Francisco G Cosio; Pierre Jais; Gerhard Hindricks; Mark E Josephson; Roberto Keegan; Bradley P Knight; Karl-Heinz Kuck; Deirdre A Lane; Gregory Yh Lip; Helena Malmborg; Hakan Oral; Carlo Pappone; Sakis Themistoclakis; Kathryn A Wood; Kim Young-Hoon; Carina Blomström Lundqvist Journal: Arrhythm Electrophysiol Rev Date: 2016
Authors: Jan Daniel Niederdöckl; Alexander Simon; Nina Buchtele; Nikola Schütz; Filippo Cacioppo; Julia Oppenauer; Sophie Gupta; Martin Lutnik; Sebastian Schnaubelt; Alexander Spiel; Dominik Roth; Fritz Wimbauer; Isabel Fegers-Wustrow; Katrin Esefeld; Martin Halle; Jürgen Scharhag; Thomas Laschitz; Harald Herkner; Hans Domanovits; Michael Schwameis Journal: J Pers Med Date: 2022-03-30